We could not find any results for:
Make sure your spelling is correct or try broadening your search.
MONTREAL, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has...
MONTREAL, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported...
MONTREAL, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2024...
MONTREAL, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate...
MONTREAL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 397 on the 2024 Report on Business magazine’s...
MONTREAL, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan- American (ex-US) specialty pharmaceutical company, today reported...
MONTREAL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2024...
MONTREAL, July 11, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company "), a leading pan-American (ex-US) specialty pharmaceutical company, announced today...
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1 | -1.86219739292 | 5.37 | 5.54 | 5.22 | 481073 | 5.27082757 | CS |
4 | -0.47 | -8.1881533101 | 5.74 | 5.82 | 5.09 | 227399 | 5.24853756 | CS |
12 | -0.41 | -7.21830985915 | 5.68 | 6.23 | 5.09 | 124242 | 5.46709972 | CS |
26 | -0.68 | -11.4285714286 | 5.95 | 6.23 | 5.09 | 83993 | 5.52446324 | CS |
52 | 0.02 | 0.380952380952 | 5.25 | 6.23 | 5.07 | 76826 | 5.53901307 | CS |
156 | 0.05 | 0.95785440613 | 5.22 | 6.23 | 4.28 | 119318 | 5.28046085 | CS |
260 | -2.55 | -32.6086956522 | 7.82 | 8.12 | 4.28 | 206685 | 5.72932715 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions